Cargando…

Sildenafil improves heart rate variability in dogs with asymptomatic myxomatous mitral valve degeneration

Myxomatous mitral valve degeneration (MMVD) causes an imbalance of sympathovagal activity resulted in poor cardiac outcomes. Phosphodiesterase-5 inhibitors have been revealed cardioprotective effect in patients with heart diseases. This study aimed to 1) compare the heart rate variability (HRV) betw...

Descripción completa

Detalles Bibliográficos
Autores principales:	PIRINTR, Prapawadee, SAENGKLUB, Nakkawee, LIMPRASUTR, Vudhiporn, SAWANGKOON, Suwanakiet, KIJTAWORNRAT, Anusak
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Japanese Society of Veterinary Science 2017
Materias:	Internal Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5627316/ https://www.ncbi.nlm.nih.gov/pubmed/28717064 http://dx.doi.org/10.1292/jvms.17-0016

Ejemplares similares

Long-term effect of sildenafil on echocardiographic parameters in dogs with asymptomatic myxomatous mitral valve degeneration
por: KIJTAWORNRAT, Anusak, et al.
Publicado: (2017)

Acute effect of ivabradine on heart rate and myocardial oxygen consumption in dogs with asymptomatic mitral valve degeneration
por: Pirintr, Prapawadee, et al.
Publicado: (2018)

Short-Term Effects of Sacubitril/valsartan on Echocardiographic Parameters in Dogs With Symptomatic Myxomatous Mitral Valve Disease
por: Saengklub, Nakkawee, et al.
Publicado: (2021)

Impact of a combination of pimobendan, furosemide, and enalapril on heart rate variability in naturally occurring, symptomatic, myxomatous mitral valve degeneration dogs
por: Pirintr, Prapawadee, et al.
Publicado: (2023)

Dronedarone attenuates the duration of atrial fibrillation in a dog model of sustained atrial fibrillation
por: Saengklub, Nakkawee, et al.
Publicado: (2017)

Acute effects of intravenous dronedarone on electrocardiograms, hemodynamics and cardiac functions in anesthetized dogs
por: SAENGKLUB, Nakkawee, et al.
Publicado: (2015)

An increasing electromechanical window is a predictive marker of ventricular fibrillation in anesthetized rabbit with ischemic heart
por: Limprasutr, Vudhiporn, et al.
Publicado: (2017)

Short-term effects of oral dronedarone administration on cardiac function, blood pressure and electrocardiogram in conscious telemetry dogs
por: SAENGKLUB, Nakkawee, et al.
Publicado: (2016)

Comparative effects of amiodarone and dronedarone treatments on cardiac function in a rabbit model
por: Boonhoh, Worakan, et al.
Publicado: (2019)

Preliminary Bioequivalence of an Oral Pimobendan Solution Formulation with Reference Solution Formulation in Beagle Dogs
por: Saengklub, Nakkawee, et al.
Publicado: (2022)

Myxomatous degeneration of the mitral valve
por: Neto, Felippe Lazar, et al.
Publicado: (2018)

Predictive model for the detection of pulmonary hypertension in dogs with myxomatous mitral valve disease
por: MIKAWA, Shoma, et al.
Publicado: (2014)

Sacubitril/valsartan mitigates cardiac remodeling, systolic dysfunction, and preserves mitochondrial quality in a rat model of mitral regurgitation
por: Tantisuwat, Lalida, et al.
Publicado: (2023)

Pharmacodynamics and Pharmacokinetics of Injectable Pimobendan and Its Metabolite, O-Desmethyl-Pimobendan, in Healthy Dogs
por: Pichayapaiboon, Poonavit, et al.
Publicado: (2021)

Pimobendan prevents cardiac dysfunction, mitigates cardiac mitochondrial dysfunction, and preserves myocyte ultrastructure in a rat model of mitral regurgitation
por: Boonpala, Pakit, et al.
Publicado: (2023)

Plasmatic Dimethylarginines in Dogs With Myxomatous Mitral Valve Disease
por: Valente, Carlotta, et al.
Publicado: (2021)

Right ventricular systolic and diastolic function assessed by two-dimensional speckle tracking echocardiography in dogs with myxomatous mitral valve disease
por: YUCHI, Yunosuke, et al.
Publicado: (2021)

Amlodipine decreases mitral regurgitation volume in dogs over 7 days: A study of 24 dogs with myxomatous mitral valve degeneration
por: Park, Sool Yi, et al.
Publicado: (2022)

Evaluation of antioxidant status and lipid peroxidation in dogs with myxomatous mitral valve degeneration stage B1
por: Tomsič, Katerina, et al.
Publicado: (2023)

Serum Concentrations of Leptin and Adiponectin in Dogs with Myxomatous Mitral Valve Disease
por: Kim, H.‐S., et al.
Publicado: (2016)

Assessment of heart rate turbulence in dogs with myxomatous mitral valve disease
por: dos Santos, Julio P., et al.
Publicado: (2021)

Pro-Inflammatory and Immunological Profile of Dogs with Myxomatous Mitral Valve Disease
por: Piantedosi, Diego, et al.
Publicado: (2022)

Comparison of N-terminal pro-atrial natriuretic peptide and three cardiac biomarkers for discriminatory ability of clinical stage in dogs with myxomatous mitral valve disease
por: OGAWA, Mizuki, et al.
Publicado: (2021)

Distinct Mitral Valve Proteomic Profiles in Rheumatic Heart Disease and Myxomatous Degeneration
por: Martins, Carlo de Oliveira, et al.
Publicado: (2014)

Contractile properties of the right atrial myofilaments in patients with myxomatous mitral valve degeneration
por: Bening, Constanze, et al.
Publicado: (2014)

The Role of Transforming Growth Factor-β Signaling in Myxomatous Mitral Valve Degeneration
por: Tang, Qiyu, et al.
Publicado: (2022)

Hemodynamic Effects of Protamine Infusion in Dogs with Myxomatous Mitral Valve Disease Undergoing Mitral Valvuloplasty
por: Yoshida, Tomohiko, et al.
Publicado: (2022)

The Mitral INsufficiency Echocardiographic score: A severity classification of myxomatous mitral valve disease in dogs
por: Vezzosi, Tommaso, et al.
Publicado: (2021)

Prevalence and Prognostic Importance of Pulmonary Hypertension in Dogs with Myxomatous Mitral Valve Disease
por: Borgarelli, M., et al.
Publicado: (2015)

Reliability of symmetric dimethylarginine in dogs with myxomatous mitral valve disease as kidney biomarker
por: Savarese, Alice, et al.
Publicado: (2018)

Left Atrial Strain at Different Stages of Myxomatous Mitral Valve Disease in Dogs
por: Nakamura, K., et al.
Publicado: (2017)

ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs
por: Keene, Bruce W., et al.
Publicado: (2019)

Prevalence and risk factors for atrial fibrillation in dogs with myxomatous mitral valve disease
por: Guglielmini, Carlo, et al.
Publicado: (2020)

Radiographic quantification of left atrial size in dogs with myxomatous mitral valve disease
por: Lam, Christopher, et al.
Publicado: (2021)

Serum Proteomic Profiles Reflect the Stages of Myxomatous Mitral Valve Disease in Dogs
por: Rešetar Maslov, Dina, et al.
Publicado: (2023)

Evaluation of progression of chronic kidney disease in dogs with myxomatous mitral valve disease
por: Yun, Hyejin, et al.
Publicado: (2023)

Pharmacokinetics of pimobendan after oral administration to dogs with myxomatous mitral valve disease
por: McManamey, Anna K., et al.
Publicado: (2023)

Antioxidant capacity of lipid- and water-soluble antioxidants in dogs with subclinical myxomatous mitral valve degeneration anaesthetised with propofol or sevoflurane
por: Tomsič, Katerina, et al.
Publicado: (2020)

Myxomatous Mitral Valve with Prolapse and Flail Scallop
por: Fan, Jerry, et al.
Publicado: (2016)

Mitral valvuloplasty with left atrial appendage closure and pacemaker implantation in a dog with severe myxomatous mitral valve degeneration: a case report
por: Yoshida, Tomohiko, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_i82s21b4r2bobtd58l8322a52i